{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/mirabegron/","result":{"pageContext":{"chapter":{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron","depth":2,"htmlHeader":"<!-- begin field 84d34ac6-5202-446b-990b-8547cb46988c --><h2>Mirabegron</h2><!-- end field 84d34ac6-5202-446b-990b-8547cb46988c -->","summary":"","htmlStringContent":"<!-- begin item 744e6272-c683-4a78-8dbc-6bf7efcc3ace --><!-- end item 744e6272-c683-4a78-8dbc-6bf7efcc3ace -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e0f9ec74-cecf-5ce1-accd-2d92d90126db","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 84e75439-5378-4889-9322-e59aea13fe1a --><h3>What are the contraindications and cautions for mirabegron?</h3><!-- end field 84e75439-5378-4889-9322-e59aea13fe1a -->","summary":"","htmlStringContent":"<!-- begin item 2f8d0d06-0dd7-47ae-b572-2fade06e62b8 --><!-- begin field 87b4ab54-7b5b-459a-b4ae-0e8450854170 --><ul><li><strong>Do not prescribe mirabegron </strong><strong>to people with:</strong><ul><li>Severe uncontrolled hypertension (systolic blood pressure of 180 mmHg or higher and/or diastolic blood pressure of 110 mmHg or higher) — measure blood pressure before starting treatment with mirabegron and monitor regularly during treatment, especially in people with hypertension.</li><li>Severe hepatic impairment.</li><li>Moderate hepatic impairment who are also taking strong cytochrome P450 inhibitors, such as itraconazole, ritonavir, and clarithromycin.</li><li>End stage renal disease (estimated glomerular filtration rate [eGFR] less than 15 mL/minute/1.73 m<sup>2</sup>).</li><li>Severe renal impairment (eGFR 15–29 mL/minute/1.73 m<sup>2 </sup>) who are also taking strong cytochrome P450 inhibitors, such as itraconazole, ritonavir, and clarithromycin.</li></ul></li><li><strong>Use mirabegron with caution in people with:</strong><ul><li>Bladder outlet obstruction.</li></ul></li><li><strong>Reduce the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/mirabegron/#dose-initiation-titration\">starting dose</a> of mirabegron to 25 mg once daily in people with:</strong><ul><li>Moderate hepatic impairment.</li><li>Mild hepatic impairment who are also taking a strong cytochrome P450 inhibitor, such as clarithromycin, itraconazole, and ritonavir.</li><li>Severe renal impairment (eGFR 15–29 mL/minute/1.73 m<sup>2</sup>).</li><li>Mild to moderate renal impairment (eGFR 30–89 mL/minute/1.73 m<sup>2</sup>) who are also taking a strong cytochrome P450 inhibitor, such as clarithromycin, itraconazole, and ritonavir.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 87b4ab54-7b5b-459a-b4ae-0e8450854170 --><!-- end item 2f8d0d06-0dd7-47ae-b572-2fade06e62b8 -->","subChapters":[]},{"id":"c2804ad5-6345-5fe8-af4b-94d1366506b6","slug":"dose-initiation-titration","fullItemName":"Dose - initiation and titration","depth":3,"htmlHeader":"<!-- begin field c831aa19-4073-4ce3-94bb-bcc3e57174ab --><h3>How should I start and titrate mirabegron?</h3><!-- end field c831aa19-4073-4ce3-94bb-bcc3e57174ab -->","summary":"","htmlStringContent":"<!-- begin item 2cead247-6197-48eb-b76d-418447ef6303 --><!-- begin field 8b56b663-d1e9-425c-aadd-0ec467e4f85f --><ul><li><strong>The recommended starting dose of mirabegron is 50 mg once daily.</strong></li><li><strong>A recommended starting dose of 25 mg daily is recommended for people with:</strong><ul><li>Moderate hepatic impairment.</li><li>Mild hepatic impairment who are also taking a strong cytochrome P450 inhibitor, such as clarithromycin, itraconazole, and ritonavir.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] 15–29 mL/minute/1.73 m<sup>2</sup>).</li><li>Mild to moderate renal impairment (eGFR 30–89 mL/minute/1.73 m<sup>2</sup>) who are also taking a strong cytochrome P450 inhibitor, such as clarithromycin, itraconazole, and ritonavir.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field 8b56b663-d1e9-425c-aadd-0ec467e4f85f --><!-- end item 2cead247-6197-48eb-b76d-418447ef6303 -->","subChapters":[]},{"id":"115191b6-76d6-5033-b31f-a6e3f583f2d0","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6c58058d-e887-47bb-abd4-d7454da445da --><h3>What are the adverse effects of mirabegron?</h3><!-- end field 6c58058d-e887-47bb-abd4-d7454da445da -->","summary":"","htmlStringContent":"<!-- begin item aefe388c-1617-4275-bd48-7ef0b9333af7 --><!-- begin field a2d4db18-8f08-44e4-9116-de92290ff86b --><ul><li><strong>Adverse effects of mirabegron include:</strong><ul><li>Common and very common —<strong> </strong>arrhythmias, constipation, diarrhoea, dizziness, headache, increased risk of infection (for example urinary tract infections), and nausea.</li><li>Uncommon — cystitis, dyspepsia, gastritis, joint swelling, palpitations, and skin reactions.</li><li>Rare or very rare — angioedema, eyelid oedema, hypersensitivity vasculitis, hypertensive crisis, lip swelling, and urinary retention.</li><li>Frequency not known — insomnia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]</p><!-- end field a2d4db18-8f08-44e4-9116-de92290ff86b --><!-- end item aefe388c-1617-4275-bd48-7ef0b9333af7 -->","subChapters":[]},{"id":"dc9a651a-a566-59c0-9ba5-a0339089cc67","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e4b31665-1f35-429f-a27b-669f51ef1135 --><h3>What are the key drug interactions of mirabegron?</h3><!-- end field e4b31665-1f35-429f-a27b-669f51ef1135 -->","summary":"","htmlStringContent":"<!-- begin item 19a56881-bc95-4cb4-a7a0-921a187959e6 --><!-- begin field f3ec1636-4f6f-4734-a677-f9de9e438c32 --><ul><li><strong>Drug interactions of mirabegron incl</strong><strong>ude </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li><strong>Strong cytochrome P450 inhibitors </strong>— plasma concentrations of mirabegron may be increased by concurrent use with strong cytochrome P450 inhibitors.<ul><li>Avoid or reduce the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/mirabegron/#dose-initiation-titration\">starting dose</a> of mirabegron in people with hepatic or renal impairment who are also taking a strong cytochrome P450 inhibitor, such as clarithromycin, itraconazole, and ritonavir. </li></ul></li><li><strong>Dabigatran </strong>— be aware that mirabegron is predicted to increase the exposure to dabigatran. </li><li><strong>Digoxin </strong>—<strong> </strong>concurrent use with mirabegron increases the plasma concentration of digoxin.<ul><li>Reduce initial dose of digoxin.</li></ul></li><li><strong>Metoprolol </strong>—<strong> </strong>mirabegron increases the plasma concentration of metoprolol.<ul><li>If concomitant use is necessary, consider reducing the dose of metoprolol.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of mirabegron, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field f3ec1636-4f6f-4734-a677-f9de9e438c32 --><!-- end item 19a56881-bc95-4cb4-a7a0-921a187959e6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}